EdgarLookup

NU RIDE INC. — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that NU RIDE INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
-1.3%
Return on Assets
Net income ÷ assets
2.31x
Debt-to-Equity
Total liabilities ÷ equity

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($619.0K) Mar 26, 2026
FY2025 Dec 31, 2024 ($8.14M) Mar 26, 2026
FY2024 Dec 31, 2023 ($343.07M) Mar 28, 2025
FY2023 Dec 31, 2022 ($282.40M) Feb 29, 2024
FY2022 Dec 31, 2021 ($410.37M) Mar 6, 2023
FY2022 Dec 31, 2020 ($124.05M) Mar 6, 2023
FY2021 Dec 31, 2019 ($10.39M) Feb 28, 2022
FY2019 Dec 31, 2018 ($1.7K) Mar 25, 2020

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($3.76M) Mar 26, 2026
FY2025 Dec 31, 2024 ($10.89M) Mar 26, 2026
FY2024 Dec 31, 2023 ($348.90M) Mar 28, 2025
FY2023 Dec 31, 2022 ($387.30M) Feb 29, 2024
FY2022 Dec 31, 2021 ($400.49M) Mar 6, 2023
FY2022 Dec 31, 2020 ($102.28M) Mar 6, 2023
FY2021 Dec 31, 2019 ($10.39M) Feb 28, 2022
FY2019 Dec 31, 2018 ($1.7K) Mar 25, 2020

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2024 Dec 31, 2023 $33.34M Mar 28, 2025
FY2023 Dec 31, 2022 $107.82M Feb 29, 2024
FY2022 Dec 31, 2021 $284.02M Mar 6, 2023
FY2022 Dec 31, 2020 $70.97M Mar 6, 2023
FY2021 Dec 31, 2019 $5.87M Feb 28, 2022

SG&A Expense

Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $6.77M Mar 26, 2026
FY2025 Dec 31, 2024 $12.90M Mar 26, 2026
FY2024 Dec 31, 2023 $54.41M Mar 28, 2025

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($7.23M) Mar 26, 2026
FY2025 Dec 31, 2024 ($35.08M) Mar 26, 2026
FY2024 Dec 31, 2023 ($137.17M) Mar 28, 2025
FY2023 Dec 31, 2022 ($213.76M) Feb 29, 2024
FY2022 Dec 31, 2021 ($387.99M) Mar 6, 2023
FY2022 Dec 31, 2020 ($99.60M) Mar 6, 2023
FY2021 Dec 31, 2019 ($5.20M) Feb 28, 2022

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2024 Dec 31, 2023 $10.15M Mar 28, 2025
FY2023 Dec 31, 2022 $54.57M Feb 29, 2024
FY2022 Dec 31, 2021 $284.51M Mar 6, 2023
FY2022 Dec 31, 2020 $52.65M Mar 6, 2023
FY2021 Dec 31, 2019 $133.0K Feb 28, 2022

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $46.97M Mar 26, 2026
FY2025 Dec 31, 2024 $53.18M Mar 26, 2026
FY2024 Dec 31, 2023 $92.17M Mar 28, 2025
FY2023 Dec 31, 2022 $452.31M Feb 29, 2024
FY2022 Dec 31, 2021 $688.78M Mar 6, 2023
FY2021 Dec 31, 2020 $767.22M Feb 28, 2022
FY2020 Dec 31, 2019 $33.55M Jun 8, 2021
FY2019 Dec 31, 2018 $120.0K Mar 25, 2020

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $6.00M Mar 26, 2026
FY2025 Dec 31, 2024 $10.95M Mar 26, 2026
FY2024 Dec 31, 2023 $45.87M Mar 28, 2025
FY2023 Dec 31, 2022 $70.28M Feb 29, 2024
FY2022 Dec 31, 2021 $149.18M Mar 6, 2023
FY2021 Dec 31, 2020 $136.48M Feb 28, 2022
FY2020 Dec 31, 2019 $24.99M Jun 8, 2021
FY2019 Dec 31, 2018 $96.7K Mar 25, 2020

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $2.60M Mar 26, 2026
FY2025 Dec 31, 2024 $6.78M Mar 26, 2026
FY2025 Dec 31, 2023 $13.55M Mar 26, 2026
FY2024 Dec 31, 2022 $351.77M Mar 28, 2025
FY2023 Dec 31, 2021 $539.60M Feb 29, 2024
FY2022 Dec 31, 2020 $630.74M Mar 6, 2023
FY2022 Dec 31, 2019 $8.56M Mar 6, 2023
FY2021 Apr 29, 2019 $0 Feb 28, 2022
FY2019 Dec 31, 2018 $23.4K Mar 25, 2020

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($1.18B) Mar 26, 2026
FY2025 Dec 31, 2024 ($1.18B) Mar 26, 2026
FY2024 Dec 31, 2023 ($1.17B) Mar 28, 2025
FY2023 Dec 31, 2022 ($827.21M) Feb 29, 2024
FY2022 Dec 31, 2021 ($544.81M) Mar 6, 2023
FY2021 Dec 31, 2020 ($134.44M) Feb 28, 2022
FY2020 Dec 31, 2019 ($10.39M) Jun 8, 2021
FY2019 Dec 31, 2018 ($1.7K) Mar 25, 2020

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $34.44M Mar 26, 2026
FY2025 Dec 31, 2024 $23.10M Mar 26, 2026
FY2024 Dec 31, 2023 $87.10M Mar 28, 2025
FY2023 Dec 31, 2022 $121.36M Feb 29, 2024
FY2022 Dec 31, 2021 $244.02M Mar 6, 2023
FY2021 Dec 31, 2020 $629.76M Feb 28, 2022
FY2020 Dec 31, 2019 $2.16M Jun 8, 2021
FY2019 Dec 31, 2018 $20.0K Mar 25, 2020

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 0 Mar 26, 2026
FY2025 Dec 31, 2024 0 Mar 26, 2026
FY2024 Dec 31, 2023 (21) Mar 28, 2025
FY2023 Dec 31, 2022 (20) Feb 29, 2024
FY2022 Dec 31, 2021 (2) Mar 6, 2023
FY2022 Dec 31, 2020 (1) Mar 6, 2023
FY2021 Dec 31, 2019 0 Feb 28, 2022

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 0 Mar 26, 2026
FY2025 Dec 31, 2024 0 Mar 26, 2026
FY2024 Dec 31, 2023 (21) Mar 28, 2025
FY2023 Dec 31, 2022 (20) Feb 29, 2024
FY2022 Dec 31, 2021 (2) Mar 6, 2023
FY2022 Dec 31, 2020 (1) Mar 6, 2023
FY2021 Dec 31, 2019 0 Feb 28, 2022

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2023 Dec 31, 2023 15.95M Feb 29, 2024
FY2023 Dec 31, 2022 15.93M Feb 29, 2024
FY2022 Dec 31, 2021 196.39M Mar 6, 2023
FY2022 Dec 31, 2020 168.00M Mar 6, 2023
FY2021 Dec 31, 2019 68.30M Feb 28, 2022